Structure Therapeutics Inc. SEC filings document a Cayman Islands clinical-stage biopharmaceutical issuer whose Nasdaq-listed American depositary shares each represent three ordinary shares. The filings identify the company’s ADS and ordinary-share structure, Exchange Act reporting status, material agreements, and formal corporate-governance matters.
Recent 8-K reports cover financial results and corporate updates, Regulation FD disclosures for aleniglipron clinical data, amendments to a sales agreement, executive appointment and compensation matters, and shareholder-vote results. Proxy materials describe annual general meeting proposals, director elections, auditor ratification, advisory executive-compensation votes, board governance, and related shareholder procedures.
Structure Therapeutics Inc. reported a wider quarterly loss as it ramps obesity drug development but remains very well funded. For the three months ended March 31, 2026, net loss was $75.97 million, or $0.35 per share, compared with $46.83 million a year earlier. Research and development spending rose to $66.51 million and general and administrative expenses to $22.87 million, reflecting expanded clinical programs and headcount.
The company ended the quarter with $1.46 billion in cash, cash equivalents and short-term investments and total shareholders’ equity of $1.45 billion, giving it substantial resources to fund trials. Management states this cash should support operations and key milestones, including Phase 3 studies of oral GLP‑1 agonist aleniglipron for chronic weight management, at least through the end of 2028.
Structure Therapeutics Inc. amended and restated its at-the-market sales agreement with Leerink Partners and Cantor Fitzgerald, supported by a prospectus supplement that increases potential ADS sales by an additional $150,000,000, for an aggregate offering price of up to $400,000,000.
The company reported positive Phase 2 ACCESS II results for obesity drug aleniglipron, with up to 16.3% body weight loss at 44 weeks and favorable FDA end-of-Phase 2 feedback, and plans to initiate Phase 3 in Q3 2026. Cash, cash equivalents and short-term investments totaled $1.5 billion as of March 31, 2026, including a $100.0 million upfront license fee, funding operations through the end of 2028, while Q1 2026 R&D expenses rose to $66.5 million and net loss reached $76.0 million.
GPCR amended its at-the-market program to permit up to $400,000,000 of American Depositary Shares (ADSs), each representing three ordinary shares, under an amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. The prospectus supplement states ~$58.5 million (3,040,000 ADSs) were sold to date and the remaining capacity is $341,478,784. The sales agents may sell ADSs at market prices and receive commissions of up to 3.0% of gross proceeds. The last reported sale price was $40.84 per ADS on Nasdaq.
Structure Therapeutics Inc. has called its 2026 annual general meeting for June 17, 2026 at 9:00 a.m. Pacific Time, to be held virtually via live audio webcast. Shareholders of record at 5:00 p.m. Eastern Time on April 20, 2026 may attend online and vote.
Investors will vote on three items: electing three Class III directors to terms ending at the 2029 meeting, ratifying Ernst & Young LLP as independent auditor for the year ending December 31, 2026, and approving on an advisory basis the compensation of named executive officers.
The company reports 213,213,565 ordinary shares outstanding as of the record date, with a one‑third quorum requirement. The board is classified into three staggered classes and a majority of directors are independent, with separate chair and CEO roles and active audit, compensation, nominating, and R&D committees overseeing risk, strategy, and governance.
Structure Therapeutics Inc. reported that its COO & GC, Matthew Lang, received new equity compensation awards. He was granted 184,614 restricted stock units, each representing one Ordinary Share, which vest in four equal annual installments starting on April 15, 2026, subject to his continued service. He also received a stock option for 223,776 Ordinary Shares at an exercise price of 18.08 per share, expiring on April 14, 2036. One-quarter of the option vests on the first anniversary of April 15, 2026, with the remainder vesting in 36 equal monthly installments, conditioned on continued service. The filing notes that each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. executive Matthew Lang, who serves as COO & GC, has filed an initial Form 3 as a reporting person. The filing shows no reported purchases, sales, gifts, tax withholdings, restructurings, or derivative exercises, and includes no derivative holdings in the excerpt provided.
FMR LLC, a ten percent owner of Structure Therapeutics Inc., reported open-market sales of American Depositary Shares (ADSs) of GPCR. Funds associated with FMR LLC sold 1,367 ADSs and 16,085 ADSs on April 14, 2026 at a weighted average price of $55.07 per ADS in separate transactions.
Each ADS represents three ordinary shares of Structure Therapeutics. After these sales, F-Prime Capital Partners Life Sciences Advisors Fund VI LP held 2,736 ADSs, and F-Prime Capital Partners Life Sciences Fund VI LP held 32,171 ADSs. A larger indirect position remains through ADSs representing 4,546,674 underlying ordinary shares.
Structure Therapeutics Inc. appointed Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026. He brings more than 15 years of executive experience at biopharmaceutical companies including Metsera, Lyell Immunopharma, Myovant Sciences and Gilead Sciences, as well as prior law firm experience.
Under his employment agreement, Mr. Lang will receive a base salary of $560,000 per year and an annual discretionary bonus targeted at 40% of salary, with no pro‑ration for 2026. He will be granted an option to purchase 223,776 ordinary shares, time-based RSUs for 184,614 ordinary shares and performance-based RSUs for 46,155 ordinary shares, all subject to multi-year vesting tied to service and specified performance milestones through 2029.
Structure Therapeutics Inc. Chief Development Officer Ashley Hall reported compensation-related equity grants. Hall received an option to buy 59,073 ordinary shares at an exercise price of $16.82 per share, expiring on March 18, 2036, and now holds 59,073 derivative shares from this grant.
Hall was also awarded 47,706 restricted stock units, each representing one ordinary share, bringing direct ordinary share holdings to 155,187 shares after the award. The RSUs vest 1/4 each year on the anniversaries of March 1, 2026, while the option vests 1/4 on March 1, 2027 and monthly thereafter, subject to continued service.